ach of the 4 cardinal acidÀbase disorders comprises a primary change in either of the determinants of blood pH (i.e., PaCO 2 and [HCO 3 À ]) and a secondary response in the countervailing determinant. [1] [2] [3] Quantified empirically, these secondary responses are directional and proportional to the primary changes, and tend to minimize the impact on systemic acidity engendered by the primary changes. Knowledge of the quantitative aspects (i.e., the slope) of the secondary response to each cardinal acid-base disorder is essential to assessing whether the prevailing acid-base status is consistent with a simple versus a mixed acid-base disorder; therefore, such knowledge has both diagnostic and therapeutic implications. [1] [2] [3] Respiratory acidosis (primary hypercapnia) is initiated by an increase in PaCO 2 , which acidifies body fluids. 3, 4 Acutely, the acidemia is ameliorated within 5 to 10 minutes by a secondary increase in plasma [HCO 3 -] that originates from titration of nonbicarbonate buffers. [4] [5] [6] [7] Observations in normal dogs and humans within an environmental chamber revealed a D[HCO 3 -]/DPaCO 2 slope of 0.1 mEq/l per mm Hg. 5, 8 An essentially identical slope is obtained in humans in whom respiratory acidosis is induced by endogenous hypercapnia.
Chronic hypercapnia (duration of several days to longer) elicits a larger increase in plasma ] that reflects stimulation of renal acidification and further ameliorates systemic acidity. 3, 4, 9, 10 Studies in normal dogs within an environmental chamber revealed that 3 to 5 days of exposure are required for the renal adaptation to reach completion, thereby establishing a new steady state of acid-base equilibrium. 11, 12 Over a PaCO 2 range between 40 and 90 mm Hg, a D[HCO 3 -]/DPaCO 2 slope of 0.3 mEq/l per mm Hg is obtained. 3, 4, 9, 11 The secondary response to chronic respiratory acidosis in humans remains uncertain. Studies in normal humans have been precluded by the severe discomfort produced by prolonged exposure to high fractions of inspired CO 2 17 The patients had no complicating conditions and were not taking medications that could affect acidbase status. However, only a single measurement was available on each of the 18 patients, thereby making questionable the presence of steady-state chronic hypercapnia. 3 Because of the prevailing uncertainty, we carried out a prospective study in outpatients with stable hypercapnic respiratory failure and evidencing a steady state of chronic hypercapnia to quantify the secondary response to chronic respiratory acidosis.
METHODS

Study Design
We conducted a prospective, single-center study at the Outpatient Pulmonary Clinic of the Hospital María Ferrer, Buenos Aires, Argentina, from January 2013 through December 2015. Eligible patients were adults ($18 years of age) with known chronic obstructive or restrictive pulmonary disease, chronic CO 2 retention, and adequate kidney function (estimated glomerular filtration rate [eGFR] $ 60 ml/min per 1.73 m 2 ), who were attending a routine clinic appointment and were clinically stable. Clinical stability was defined by the absence of worsening of pulmonary symptomatology, vomiting, diarrhea, and changes in prescribed or over-the-counter medications over the preceding 4 weeks, as well as hemodynamic stability on physical examination at the clinic appointment. In addition, patients should not have taken diuretics, steroids, carbonic anhydrase inhibitors, alkali, angiotensinconverting enzyme inhibitors, or angiotensin receptor blockers over the preceding 4 weeks.
Eligible patients were invited to participate in the study, and those who accepted provided signed informed consent. The study involved measurement of arterial blood gases and a panel of plasma chemistries on the day of the appointment, and a repeat measurement within a 10-day period. We used the analysis of covariance method to compare both intercepts and slopes. We first tested for the equality of the slopes while allowing for the intercepts to be different; if the slopes were not statistically significantly different, we tested for the equality of the intercepts by assuming a common slope. Analyses were performed using SAS Enterprise Guide (version 7.12; SAS Institute, Cary, NC) and R language.
RESULTS
A total of 35 patients were invited and agreed to participate in the study. Of these, 29 patients completed both measurements; 6 patients did not report for the second measurement. On completion of the study, 1 patient was excluded because she was not in a steady state of PaCO 2 (values of 63.4 and 54.3 mm Hg, range of 9.1 mm Hg). The remaining 28 patients comprised our analytical set.
Characteristics of the Study Cohort
Patients' mean age was 55.4 AE 12.7 years, and most patients (75%) were men. The mean height was 164.7 AE 8.6 cm, mean weight 76.9 AE 24.8 kg, and mean body mass index (BMI) 28.3 AE 9.6 kg/m 2 . In all, 20 patients had chronic obstructive pulmonary disease, 3 pulmonary interstitial disease, 3 bronchiectasis, and 2 cystic fibrosis. A total of 16 patients were maintained on home oxygen. Three patients had type 2 diabetes mellitus and were maintained on oral antidiabetic medications.
Evidence for a Steady State of PaCO 2
The mean interval between the 2 measurements was 7.2 AE 2.1 days (in 1 patient, the interval was 12 days, exceeding the designated 10-day period). The mean PaCO 2 was 53.5 AE 6.2 and 52.1 AE 6.3 mm Hg on the first and second measurement, respectively (P ¼ 0.03). The mean range of PaCO 2 between the 2 measurements of each patient was 2.8 AE 2.1 mm Hg. In 18 patients (64%), the range of PaCO 2 between the 2 measurements was <3.0 mm Hg. Compared with the first measurement, the second measurement of PaCO 2 decreased by $1.0 mm Hg in 14 patients (50%), increased by $ 1.0 mm Hg in 8 patients (29%), and remained essentially unchanged (change < 1.0 mm Hg) in 6 patients (21%). Figure 1 depicts the 2 measurements of PaCO 2 in the 28 patients.
Plasma Data and Correlations
Steady-state plasma values were obtained for each patient by averaging the 2 plasma determinations made. For the group as a whole, Table 1 Figure 2 and Table 2 . 13, 14 The first study analyzed data of 420 unselected patients (88% inpatients) referred for evaluation or treatment of chronic lung disease. 13 No evidence for a steady state of PaCO 2 was sought; 65% of patients were under active treatment, including diuretics, and 9% of patients had moderate kidney insufficiency. The authors conceded that, in some patients, complicating acid-base disorders were likely superimposed on hypercapnia. The second analysis involved 20 inpatients with decompensated hypercapnic respiratory failure.
14 Patients had no kidney disease or "overt diabetes mellitus." After medical stabilization, each patient contributed 2 to 3 acid-base measurements over a period of steadystate chronic hypercapnia (3-14 days), with PaCO 2 varying by no more than AE4 mm Hg from the average PaCO 2 in a given patient. During the steady-state period, patients had no apparent complicating condition that could affect acid-base status, nor were they receiving diuretics or steroids.
A third retrospective study also from that era analyzed 28 periods of steady-state hypercapnia in 13 patients (18 months to 23 years of age) with cystic fibrosis hospitalized with acute respiratory decompensation. 15 No patient had kidney disease. The steadystate period was defined by daily PaCO 2 values (at least 2 values per patient) that varied by no more than AE10% from the mean PaCO 2 of the period in a given patient. No patient had shock or vomiting, nor was any patient taking diuretics or steroids during the steadystate period. Acid-base data were averaged for each Contrasted with studies in hospitalized patients, a recent retrospective study of 18 outpatients with stable hypercapnic respiratory failure reported a substantially 17 showed that the intercepts, but not the slopes, were significantly different (Figure 4) Our findings call for discarding the currently held D Table 2 .
Although plasma pH had a significant inverse relationship with PaCO 2 in our study, only 21% of our subjects had pH values of <7.36, the reported lower limit of normal. 22 The predicted pH values in our study are marginally more acidemic than those in 2 previous studies in hospitalized patients 14, 15 and mildly more acidemic than the study of Martinu et al. 17 ( Figure 5 ). Substantially more acidemia is predicted by 1 of the previous studies in hospitalized patients 13 and a study in dogs. 11 The limits of the 95% prediction intervals for plasma pH and [H þ ] during mild to moderate chronic hypercapnia presented in Table 2 indicate that systemic acidity varies between the mid-normal range and mild acidemia, highlighting a remarkably effective secondary response. Our results bolster the experimental evidence that changes in systemic acidity do not drive the renal responses to increases or decreases in PaCO 2 . [23] [24] [25] Nor are changes in intracellular pH, whether whole-body 26 or kidney-specific, 27, 28 prerequisite for these responses. Rather, the change in PaCO 2 itself appears to provide the signal that triggers the corresponding renal acidification response to chronic hypercapnia or chronic hypocapnia. [23] [24] [25] [26] 29 The renal response to chronic hypercapnia entails a transient increase in net acid excretion, largely as ammonium, which generates the characteristic hyperbicarbonatemia, and a persistent increase in bicarbonate reabsorption, which sustains the generated hyperbicarbonatemia. 4, [9] [10] [11] [12] 25 No systematic information exists on the impact of chronic kidney disease on the renal response to chronic hypercapnia. In a patient with hyporeninemic hypoaldosteronism, hyperkalemia, and an eGFR of w20 ml/min per 1.73 m 2 , the secondary response to chronic hypercapnia was suppressed; however, correction of the hyperkalemia enabled an essentially normal secondary response, likely by disinhibiting renal ammoniagenesis. 30 This report suggests that in the absence of hyperkalemia, only advanced chronic kidney disease would suppress the secondary response to chronic hypercapnia. Notably, our patients had preserved kidney function, and none featured hyperkalemia.
Adaptation to chronic hypercapnia in the dog requires 3 to 5 days to reach completion. 4, 9, 11, 12, 25 Whether this temporal pattern applies to humans is unknown. Dogs were studied within an environmental chamber, each level of hypercapnia being introduced abruptly and then sustained for a period of 7 days or longer. In patients, chronic hypercapnia often reflects gradual deterioration in pulmonary function. Consequently, the secondary response might essentially keep pace with the slowly rising PaCO 2 without a perceptible delay.
Like previous studies in dogs and humans, our study demonstrates that chronic hypercapnia does not cause appreciable changes in plasma [Na
concentration, and anion gap. 4, 9 The renal adaptation to chronic hypercapnia entails chloruresis, which generates the characteristic hypochloremia (Table 1) . 4, 9 Our study has several strengths. It is the first prospective study to examine the secondary response to chronic hypercapnia in outpatients with chronic CO 2 retention. Our patients were in stable respiratory status, had sound hemodynamics and adequate kidney function, and did not have complicating conditions or take medications that could affect their acid-base status. Evidence for the presence of a steady state of chronic hypercapnia was provided. However, we were unable to recruit patients with chronic PaCO 2 level beyond 70 mm Hg.
In summary, our study describes the slope of the secondary response to chronic respiratory acidosis in humans. The results allow estimation of the prediction limits within which plasma [HCO 3 À ] and pH should fall with 95% confidence at a given level of steady-state PaCO 2 in chronic respiratory acidosis. This reference range enables the clinician to differentiate between simple chronic respiratory acidosis and hypercapnia coexisting with additional acid-base disorders.
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